The Muppet to be named Julia already exits, but will get her autism depute on April 10th according to PBS and Sesame Street. It is in collaboration and a campaign awareness with Autism Speaks. Autism has also been linked to vaccines. The irony here is that Elmo and the surgeon general promoted that vaccines were safe, and to “tell your friends to get vaccinated too” as part of the ad campaign. PBS seems to want children under ten to be indoctrinated with promoting vaccines. What is a seven year old supposed to do pressure his or her mother?
Back in late 2015 Florida Congressman Bill Posey urged congress to investigate the CDC (Center for Disease Control) about a claim that MMR vaccines lead to high incidence of autism.
Nothing seems to have come of that. The Food and Drug Administration (FDA) has approved two drugs for treating irritability associated with the autism (risperidone and aripiprazole). Risperidone is actually an antipsychotic medicine. It is another one of those drugs that change the brains chemicals. If you believe that nonsense that all you are is a test tube. Risperidone is used to treat schizophrenia and symptoms of bipolar disorder or manic depression. It is also used in autistic children to treat symptoms of irritability. It is approved for use in psychotic conditions related to dementia. Pharmaceutical companies like the one drugs fits all conditions, so their duped doctors just prescribe them at will.
Aripiprazole is an antipsychotic. It is prescribed to treat agitation associated with schizophrenia or bipolar disorder, also known as manic-depression. Abilify is an aripiprazole drug. Strange though Abilify’s ad campaign is if your anti-depressant doesn’t work then you may need to add Abilify. There ads tell everyone that the products don’t work.
A person who is autistic has difficulty with communication, learns slower, and has social challenges. The bird brain pharma frauds have not come up with a drug to directly assist communication issues with autistic kids, but we are sure they will. They will call it a chemical problem in the brain, and mixes some powder with a drop of this or that and markets it as a solution. They used to call it snake oil years ago, or maybe pharma is autistic.
Pharma has gotten many to believe that the human body is a bunch or chemicals. And that your chemicals are all out of whack thus you need more chemicals to put those stray ones back together. Way too many people have bought into this non-sense, even good doctors included. It is all about money, and not solutions.
If you know organic all natural products are the way to go, then pharma drugs are not for you.
Showing posts with label vaccines. Show all posts
Showing posts with label vaccines. Show all posts
Saturday, April 1, 2017
Wednesday, October 12, 2011
US Supreme Court Rules in Favor of Pharma on Vaccines, Data Mining and Generics. Who is Looking Out for You?
United States: Supreme Court Rules In IMS Data Mining Case
by Maria Buckley
On June 23, 2011, the Supreme Court in Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc. et al1, struck down a Vermont law2 that bans the sale of physicians' prescribing information to pharmaceutical companies and further bans pharmaceutical companies from using such data to market their products. The Supreme Court's 6-3 opinion by Justice Kennedy found that the Vermont law unconstitutionally restricted the pharmaceutical companies' right to free speech.
Vermont's Prescription Confidentiality Law provides that absent the prescriber's consent, pharmacies and other related entities are prohibited from selling prescriber identifiable information for marketing purposes and that such information cannot be used by pharmaceutical manufacturers to market their products. The statue permits other uses of the data, e.g., healthcare research.
The Court found that speech in the process of pharmaceutical marketing is a form of expression protected by the free speech clause of the first amendment. Therefore, the Vermont statue must be subjected to heightened judicial scrutiny of the reasons for the restrictions on speech.
Vermont's justification was that the law was necessary to protect medical privacy, avoid physician harassment by drug company representatives, and to preserve the integrity of the doctor-patient relationship. Vermont further argued that the statute is integral to its efforts to control healthcare costs and improve public health.
HEALTH News
Supreme Court Rules in Favor of Vaccine Manufacturers
SCOTUS makes it more difficult to sue manufacturers in autism cases.
By Meghan McCarthy
The Supreme Court Feb 22, 2011 ruled that vaccine companies cannot be sued for design defects, handing the pharmaceutical industry a victory and making it more difficult to bring cases against vaccine manufacturers for allegedly causing autism.
A 1986 law established a federal system for compensating patients injured by "unavoidable" side effects after being given a vaccine. The law aimed to make collecting damages for children injured by vaccines easier and faster by giving the Health and Human Services Department the authority to hear the cases and hand out compensation, funded by an excise tax on pharmaceutical companies making vaccines. President Obama’s fiscal 2012 budget estimated the vaccine fund would have $3 billion. The fund has paid out over $2.5 billion since its inception.
A ruling that allowed suits against the vaccine producers for a "design defect" might have opened up the pharmaceutical industry to thousands of cases alleging that vaccines caused autism in children.
The case heard by the Supreme Court, brought by Russell and Robalee Bruesewitz, alleged that their daughter Hannah was disabled by a diphtheria, tetanus, and pertussis (DTP) vaccine she received as an infant in 1992 manufactured by Lederle Laboratories, now owned by Pfizer Inc.’s Wyeth unit. After the family was denied compensation in the federal vaccine court in 1995, they filed the suit that ultimately reached the Supreme Court, charging that the defective design of the vaccine caused their daughter’s disabilities and that the company could be held liable for negligent design under Pennsylvania law.
Supreme Court Rejects Generic Drug Labeling Suits
Reuters by James Vicini June 23, 2011
(Reuters) - The Supreme Court ruled on Thursday that generic drug companies cannot be sued under state law over allegations that they failed to provide adequate label warnings about potential side effects.
By a 5-4 vote, the justices gave a victory to Israel's Teva Pharmaceutical Industries Ltd, Mylan Inc's UDL Laboratories and Iceland-based Actavis Inc by overturning U.S. appeals court rulings that allowed such lawsuits.
The companies argued that federal law barred such lawsuits because the drug had been approved by the U.S. Food and Drug Administration (FDA). Federal law requires generic drugs to have the same labels as their brand name equivalents.
Justice Clarence Thomas in the court's majority opinion agreed. He said federal drug regulations applicable to generic drug manufacturers directly conflicted with and thus pre-empted state lawsuits.
The Supreme Court decided a related issue in 2009 when it ruled FDA drug regulations do not protect pharmaceutical companies from being sued under state law over drug labeling, a case involving Pfizer Inc's Wyeth unit and its antinausea drug Phenergan.
But in the generic drug cases, the justices reversed separate U.S. appeals court rulings that the lawsuits against the companies could go forward.
The high court agreed with the arguments of the generic drug makers that they had no choice but to use the same drug labels as the brand manufacturer.
Teva, Actavis and the Generic Pharmaceutical Association hailed the ruling.
The court ruled 6-2 to uphold the ruling of the 3rd Circuit appellate court, finding that the federal law preempts all “design-defect claims” made against vaccine manufacturers. Justice Antonin Scalia, writing for the majority, said the statute only holds manufacturers liable for proper manufacturing and labeling, not for the actual design of the drug.
by Maria Buckley
On June 23, 2011, the Supreme Court in Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc. et al1, struck down a Vermont law2 that bans the sale of physicians' prescribing information to pharmaceutical companies and further bans pharmaceutical companies from using such data to market their products. The Supreme Court's 6-3 opinion by Justice Kennedy found that the Vermont law unconstitutionally restricted the pharmaceutical companies' right to free speech.
Vermont's Prescription Confidentiality Law provides that absent the prescriber's consent, pharmacies and other related entities are prohibited from selling prescriber identifiable information for marketing purposes and that such information cannot be used by pharmaceutical manufacturers to market their products. The statue permits other uses of the data, e.g., healthcare research.
The Court found that speech in the process of pharmaceutical marketing is a form of expression protected by the free speech clause of the first amendment. Therefore, the Vermont statue must be subjected to heightened judicial scrutiny of the reasons for the restrictions on speech.
Vermont's justification was that the law was necessary to protect medical privacy, avoid physician harassment by drug company representatives, and to preserve the integrity of the doctor-patient relationship. Vermont further argued that the statute is integral to its efforts to control healthcare costs and improve public health.
HEALTH News
Supreme Court Rules in Favor of Vaccine Manufacturers
SCOTUS makes it more difficult to sue manufacturers in autism cases.
By Meghan McCarthy
The Supreme Court Feb 22, 2011 ruled that vaccine companies cannot be sued for design defects, handing the pharmaceutical industry a victory and making it more difficult to bring cases against vaccine manufacturers for allegedly causing autism.
A 1986 law established a federal system for compensating patients injured by "unavoidable" side effects after being given a vaccine. The law aimed to make collecting damages for children injured by vaccines easier and faster by giving the Health and Human Services Department the authority to hear the cases and hand out compensation, funded by an excise tax on pharmaceutical companies making vaccines. President Obama’s fiscal 2012 budget estimated the vaccine fund would have $3 billion. The fund has paid out over $2.5 billion since its inception.
A ruling that allowed suits against the vaccine producers for a "design defect" might have opened up the pharmaceutical industry to thousands of cases alleging that vaccines caused autism in children.
The case heard by the Supreme Court, brought by Russell and Robalee Bruesewitz, alleged that their daughter Hannah was disabled by a diphtheria, tetanus, and pertussis (DTP) vaccine she received as an infant in 1992 manufactured by Lederle Laboratories, now owned by Pfizer Inc.’s Wyeth unit. After the family was denied compensation in the federal vaccine court in 1995, they filed the suit that ultimately reached the Supreme Court, charging that the defective design of the vaccine caused their daughter’s disabilities and that the company could be held liable for negligent design under Pennsylvania law.
Supreme Court Rejects Generic Drug Labeling Suits
Reuters by James Vicini June 23, 2011
(Reuters) - The Supreme Court ruled on Thursday that generic drug companies cannot be sued under state law over allegations that they failed to provide adequate label warnings about potential side effects.
By a 5-4 vote, the justices gave a victory to Israel's Teva Pharmaceutical Industries Ltd, Mylan Inc's UDL Laboratories and Iceland-based Actavis Inc by overturning U.S. appeals court rulings that allowed such lawsuits.
The companies argued that federal law barred such lawsuits because the drug had been approved by the U.S. Food and Drug Administration (FDA). Federal law requires generic drugs to have the same labels as their brand name equivalents.
Justice Clarence Thomas in the court's majority opinion agreed. He said federal drug regulations applicable to generic drug manufacturers directly conflicted with and thus pre-empted state lawsuits.
The Supreme Court decided a related issue in 2009 when it ruled FDA drug regulations do not protect pharmaceutical companies from being sued under state law over drug labeling, a case involving Pfizer Inc's Wyeth unit and its antinausea drug Phenergan.
But in the generic drug cases, the justices reversed separate U.S. appeals court rulings that the lawsuits against the companies could go forward.
The high court agreed with the arguments of the generic drug makers that they had no choice but to use the same drug labels as the brand manufacturer.
Teva, Actavis and the Generic Pharmaceutical Association hailed the ruling.
The court ruled 6-2 to uphold the ruling of the 3rd Circuit appellate court, finding that the federal law preempts all “design-defect claims” made against vaccine manufacturers. Justice Antonin Scalia, writing for the majority, said the statute only holds manufacturers liable for proper manufacturing and labeling, not for the actual design of the drug.
Subscribe to:
Posts (Atom)